CMS has selected 15 new drugs for the next round of Medicare Part D price negotiations, according to a press release from HHS ...

For an extended-release formulation given once daily to offer any advantage in terms of patient convenience, better safety profile due to reduced peak concentrations and/or better or equivalent ...

A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter and Boehringer reported a Phase 3 failure.